Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akeso, Inc. (HK:9926)
HKEX:9926
Holding HK:9926?
Track your performance easily
9926 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$26.45 - HK$72.55
Previous CloseHK$72.2
Volume6.87M
Average Volume (3M)6.45M
Market Cap
HK$62.51B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Mar 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares OutstandingN/A
10 Day Avg. Volume14,485,623
30 Day Avg. Volume6,451,003
Standard Deviation0.20
R-Squared0.07
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$65.31Price Target Upside-9.54% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Akeso, Inc. News
PremiumCompany Announcements
Akeso’s Ivonescimab Shows Promise in NSCLC Treatment
PremiumCompany Announcements
Akeso, Inc. Reports Mixed Mid-Year Financial Results
PremiumCompany Announcements
Akeso, Inc. Schedules Key Financial Review Meeting
PremiumCompany Announcements
Akeso’s Innovative Cancer Drug Advancing GloballyPremiumCompany Announcements
Akeso’s Cancer Drug Ivonescimab Shows Promising Trial Results
PremiumCompany Announcements
Akeso, Inc. Appoints New CFO, Dr. Bing Wang
PremiumCompany Announcements
Akeso, Inc. Reveals Board of Directors Structure
PremiumCompany Announcements
Akeso, Inc. Shareholders Approve Key ResolutionsBulls Say, Bears Say
Bulls Say
Drug SuperiorityAK112 demonstrated superiority over Keytruda in head-to-head comparison as a treatment for PD-L1+ non-small cell lung cancer.
Market ApprovalIvonescimab received its first NDA approval in China for EGFRmut nsNSCLC that progressed on EGFR-TKI.
Safety ProfileManagement thinks AK112's superior safety profile allows patients to stay on treatment longer.
Bears Say
Clinical Trial ResultsPublished ASCO abstract has seen lower efficacy in Phase III versus previously reported Phase II data.
Market CompetitionInnovent's sintilimab has been approved for the same indication and has a lead in its market launch.
Stock PerformanceThe share price fall of approximately 40% was triggered by weakened sentiment on the upcoming AK112-303 readout.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
2.83% Mutual Funds
5.16% Other Institutional Investors
92.01% Public Companies and
Individual Investors
9926 FAQ
What was Akeso, Inc.’s price range in the past 12 months?
Akeso, Inc. lowest stock price was HK$26.45 and its highest was HK$72.55 in the past 12 months.
What is Akeso, Inc.’s market cap?
Currently, no data Available
When is Akeso, Inc.’s upcoming earnings report date?
Akeso, Inc.’s upcoming earnings report date is Mar 26, 2025 which is in 187 days.
How were Akeso, Inc.’s earnings last quarter?
Akeso, Inc. released its earnings results on Aug 28, 2024. The company reported -HK$0.308 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.308.
Is Akeso, Inc. overvalued?
According to Wall Street analysts Akeso, Inc.’s price is currently Overvalued.
Does Akeso, Inc. pay dividends?
Akeso, Inc. does not currently pay dividends.
What is Akeso, Inc.’s EPS estimate?
Akeso, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Akeso, Inc. have?
Akeso, Inc. has 865,857,200 shares outstanding.
What happened to Akeso, Inc.’s price movement after its last earnings report?
Akeso, Inc. reported an EPS of -HK$0.308 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.897%.
Which hedge fund is a major shareholder of Akeso, Inc.?
Currently, no hedge funds are holding shares in HK:9926
---
Akeso, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-14.20%
Trailing 12-Months
Asset Growth
15.62%
Trailing 12-Months
Company Description
Akeso, Inc.
Akeso Inc is a clinical-stage biopharmaceutical company committed to in-house discovery, development, and commercialization of therapies. It is dedicated to addressing global unmet medical needs in oncology, immunology, and other therapeutic areas. The company's drug candidates include AK104 for recurrent or metastatic cervical cancer, Penpulimab (AK105) for the treatment of patients with classical Hodgkin's lymphoma, AK112 for advanced solid tumors, AK101 for the treatment of ulcerative colitis, AK111 for moderate-to-severe psoriasis, Ebronucimab (AK102) for the treatment of patients with a high or very high risk of hypercholesterolemia, and others.
---
9926 Stock 12 Month Forecast
Average Price Target
HK$65.31
▼(-9.54% Downside)
Technical Analysis
Viva Biotech Holdings
―
CanSino Biologics, Inc. Class H
―
Alphamab Oncology
―
Ximei Resources Holding Ltd.
―
Best Analysts Covering 9926
1 Year
1 Year Success Rate
4/4 ratings generated profit
1 Year Average Return
+86.78%
reiterated a buy rating 2 months ago
Copying Tony Ren's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +86.78% per trade.
---